Literature DB >> 5491877

Treatment of primary hyperoxaluria.

C E Dent, T C Stamp.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5491877      PMCID: PMC1647446          DOI: 10.1136/adc.45.244.735

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  17 in total

1.  Treatment of primary hyperoxaluria.

Authors:  L H Smith; H E Williams
Journal:  Mod Treat       Date:  1967-05

Review 2.  Disorders of oxalate metabolism.

Authors:  H E Williams; L H Smith
Journal:  Am J Med       Date:  1968-11       Impact factor: 4.965

3.  Biochemical studies on the treatment of primary hyperoxaluria.

Authors:  D A Gibbs; R W Watts
Journal:  Arch Dis Child       Date:  1967-10       Impact factor: 3.791

4.  Deficiency of 2-oxo-glutarate: glyoxylate carboligase activity in primary hyperoxaluria.

Authors:  J Koch; E L Stokstad; H E Williams; L H Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1967-04       Impact factor: 11.205

5.  Control of crystallization in urine.

Authors:  J E Howard; W C Thomas
Journal:  Am J Med       Date:  1968-11       Impact factor: 4.965

6.  Calcium carbimide in the treatment of primary hyperoxaluria.

Authors:  C C Solomons; S I Goodman; C M Riley
Journal:  N Engl J Med       Date:  1967-01-26       Impact factor: 91.245

7.  The effects of magnesium and pH on experimental calcium oxalate stone disease.

Authors:  T A Borden; E S Lyon
Journal:  Invest Urol       Date:  1969-01

8.  Effect of daily MgO and vitamin B6 administration to patients with recurring calcium oxalate kidney stones.

Authors:  S N Gershoff; E L Prien
Journal:  Am J Clin Nutr       Date:  1967-05       Impact factor: 7.045

9.  Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets.

Authors:  E S Lyon; T A Borden; J E Ellis; C W Vermeulen
Journal:  Invest Urol       Date:  1966-09

10.  Treatment of primary hyperoxaluria with calcium carbimide.

Authors:  P M Zarembski; A Hodgkinson; M Cochran
Journal:  N Engl J Med       Date:  1967-11-09       Impact factor: 91.245

View more
  13 in total

1.  The influence of calcium content of water, intake of vegetables and fruit and of other food factors upon the incidence of renal calculi.

Authors:  G A Rose; E J Westbury
Journal:  Urol Res       Date:  1975-08-08

2.  A rare twist to a common problem.

Authors:  L H Smith
Journal:  West J Med       Date:  1996-01

3.  Reduction of urinary oxalate excretion in primary hyperoxaluria by diet.

Authors:  E R Yendt; M Cohanim; L Peters
Journal:  Trans Am Clin Climatol Assoc       Date:  1980

Review 4.  Management of primary hyperoxaluria: efficacy of oral citrate administration.

Authors:  E Leumann; B Hoppe; T Neuhaus
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

5.  Hyperoxaluria and recurrent stone formation apparently cured by short courses of pyridoxine.

Authors:  A R Harrison; G P Kasidas; G A Rose
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-27

6.  Early onset of stone diseases and primary hyperoxaluria.

Authors:  R Topaloğlu; A Bakkaloğlu; U Saatçi; N Beşbaş
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

7.  [Type I oxalosis in childhood--studies within the scope of terminal renal failure in the child].

Authors:  M Frosch; E Kuwertz-Bröking; M Bulla; D B von Bassewitz; D B Leusmann
Journal:  Klin Wochenschr       Date:  1989-11-17

8.  Organic-acid transport in resealed haemoglobin-containing human erythrocyte 'ghosts'.

Authors:  A R Hubbard; U Sprandel; R A Chalmers
Journal:  Biochem J       Date:  1980-09-15       Impact factor: 3.857

9.  Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones.

Authors:  A Mitwalli; A Ayiomamitis; L Grass; D G Oreopoulos
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

10.  New aspects of infantile oxalosis.

Authors:  E P Leumann; A Niederwieser; A Fanconi
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.